People who have trouble breathing as they sleep often turn to ResMed (RMD), which makes a face-worn breathing apparatus. Its continuous positive airway pressure (CPAP) device saves lives and is driving ResMed's sales and profits higher.
On Tuesday, the Relative Strength (RS) Rating for ResMed stock climbed into a higher percentile, rising to 72, up from 68 the day before. The upgrade puts ResMed not far beneath a key benchmark. Market research shows that the best-performing stocks often have an RS Rating north of 80 as they launch their largest runs. See if ResMed can continue rising and join that elite group.
Over the last four quarters San Diego-based ResMed reported EPS growth ranging from 27% to 34% on also rising revenue growth. The company has a terrific 96 EPS Rating, putting it in the top 4% of all companies for profit growth on a current and long-term basis.
↑ X NOW PLAYING Do Your Stocks Meet This Key Standard? Here's Why Institutional Support MattersIt also boasts a 93 Composite Rating. The best growth stocks often have a 90 or higher Composite as they begin their biggest runs. And its B Accumulation/Distribution Rating shows that funds have been buying more of its shares than selling over the last 13 weeks.
↑ XResMed stock has been in a consolidation pattern for several years. It hit an all-time high just above 300 in late December 2021. It dropped to a 132.24 low in late October 2023, then started climbing again.
Can You Really Time The Stock Market?
Tuesday afternoon the sleep apnea relief device maker traded at about 237, down fractionally for the day but up nearly 80% from the October 2023 low. ResMed showed 29% earnings growth in its most recent report, to $2.43 per share. Sales increased 10% to $1.28 billion.
ResMed earns the No. 5 rank among its peers in the 125-stock Medical-Products industry group. Boston Scientific (BSX) is the No. 1-ranked stock in the group.
IBD's proprietary Relative Strength Rating measures share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Please follow James DeTar on X @JimDeTar
RELATED:
Which Stocks Are Showing Improved Price Performance?
See Stocks On The List Of Leaders Near A Buy Point
Why Should You Use IBD's Relative Strength Rating?
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
Which Stocks Are Breaking Out Or Near A Pivot Point? Check MarketSurge
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。